Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that individuals who had undergone an appendectomy showed a higher incidence of alopecia areata, with a hazard ratio of 2.27, suggesting that appendectomy may impact gut microbiome and immune regulation related to hair health.

The abstract highlights that lichen planus can manifest as cicatricial alopecia or lichen planopilaris, while discoid lupus erythematosus, a common form of lupus erythematosus, typically causes scarring alopecia. Results are not reported here.

In this study, CCCA patients were found to have higher odds of metabolic, autoimmune, atopic, and psychiatric comorbidities compared to matched controls.

In this study, tofacitinib treatment significantly reduced hair loss on the head and body, as well as nail involvement, in patients with alopecia areata over 18 months, with minimal side effects reported.

In this case series, researchers reported on the clinical characteristics and treatment approaches for Frontal Fibrosing Alopecia in four cases, emphasizing the importance of early identification and intervention to manage this scarring hair loss disorder that primarily affects the frontal hairline and eyebrows.

This research investigated immune cell involvement in various types of inflammatory alopecia by analyzing gene expression data from scalp samples, revealing distinct cellular changes in conditions like Alopecia Areata, Frontal Fibrosing Alopecia, Lichen Planopilaris, and Central Centrifugal Cicatricial Alopecia, which may inform future therapeutic targets.

In this study, researchers found that patients with severe alopecia areata show varied regrowth timelines with baricitinib, and those with the most severe cases may still experience delayed but eventual improvement.

In this case series, researchers observed a rare presentation of lichen planopilaris confined to the face in six patients, with dermoscopic and histopathological profiles indicating scarring alopecia and pigment changes, and suggested that shaving and mustard oil use might trigger the condition.

The researchers reviewed multiple studies and found that baricitinib, a JAK inhibitor, generally improved the condition of patients with severe alopecia areata, with minimal side effects.

This study found that in biopsied skin samples of alopecia areata, a lower anagen/telogen ratio was associated with increased T cell infiltration, and enhancing the PD-1/PD-L1 axis may inhibit CD8+T cell infiltration and improve the condition.

This study found that patients with alopecia areata had significantly lower frequencies of IL-10 producing CD19+CD24hiCD38hi regulatory B cells compared to healthy volunteers, suggesting a potential role for these cells in the autoimmune response seen in the condition.

This study reports that CD200R expression is significantly reduced in an experimental mouse model of scarring alopecia, suggesting a potential role for this pathway in immune regulation and hair follicle protection.

This case series reports on three school-aged children developing alopecia areata shortly after COVID-19 infection, suggesting a potential association between the virus and this autoimmune hair loss condition.

This study suggests that varicella-zoster virus infection in skin cells may play a role in segmental vitiligo's progression and depigmentation.

This study found that innate lymphoid cells-type 1 can induce alopecia areata characteristics in human hair follicles both ex vivo and in vivo, challenging the view of it as solely an autoimmune disease driven by CD8+ T cells.

This study found that the Severity of Alopecia Tool score does not predict the quality of life in patients with alopecia areata, suggesting patient-reported outcomes better reflect the impact on life quality.

This article discusses the etiology, clinical presentation, and current treatment options for alopecia areata and highlights new therapeutic modalities under investigation, but it reports no new research results.

This study observed that recognizing herpetic infection in pemphigus patients can help avoid unnecessary changes in immunosuppressive treatments for lesions wrongly presumed treatment-resistant.

This study suggests that HDAC inhibitors, such as Vorinostat and Entinostat, could be effective in promoting hair regrowth in a mouse model of alopecia areata.

This study found significant alterations in the scalp and gut microbiome of patients with alopecia areata compared to healthy controls, suggesting a potential link to systemic inflammation and autoimmune response.

This case report about anterolateral leg alopecia discusses a potentially underreported condition with no new clinical results available.

This study suggests that mitochondrial dysfunction might contribute to the pathogenesis of Lichen planopilaris by triggering a metabolic shift that leads to chronic inflammation and hair follicle damage.

This article reviews the role of the National Alopecia Areata Foundation in promoting research and collaboration to find treatments or a cure for alopecia areata and reports no clinical results.

This study reports a case where treatment with the TNF alpha inhibitor infliximab successfully resolved refractory alopecia universalis in a 41-year-old woman.

This study found no significant association between metabolic syndrome and lichen planus, but hypertension, triglycerides, and low HDLC levels were significantly associated with lichen planus.

This study suggests a connection between the unfolded protein response and upregulation of NKG2D ligands in stressed hair follicles, highlighting a potential role of PRDX5 in alopecia areata pathogenesis.

This study found that topical Vorinostat induced significant hair regrowth in mice with alopecia areata, suggesting it as a potential repurposable treatment for the condition.

This quiz presents educational questions about alopecia areata, including its diagnosis and underlying mechanisms, but reports no new clinical outcomes.

The document provides a comprehensive guide for dermatologists to diagnose and treat hair loss.

This article reviews the National Alopecia Areata Foundation's biennial research summits, aimed at advancing treatment development for alopecia areata, and reports no new results.